Byondis Seeks Partner For Lead ADC To Enter Crowded Breast Cancer Market
Positive Top-Line Results From TULIP Study
Executive Summary
Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.
You may also be interested in...
Enhertu Could Get Big Boost From Second-Line Breast Cancer Indication
An analyst forecast that about 40% of the drug’s sales could come from second-line disease, while lack of grade 4-5 interstitial lung disease events was seen as a plus.
MacroGenics Gets Nod For Margenza In HER2-Positive Breast Cancer
The drug may see a muted launch given the competitive landscape and a broad label despite its efficacy advantage in F-allele patients.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.